We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biosensor Device Uses CRISPR-Cas9 to Detect Target DNA Sequence

By LabMedica International staff writers
Posted on 01 Apr 2019
Print article
Image: A close-up of the CRISPR-Chip device (Photo courtesy of Keck Graduate Institute).
Image: A close-up of the CRISPR-Chip device (Photo courtesy of Keck Graduate Institute).
A team of biomedical engineers has developed and tested a graphene-based biosensor device that uses CRISPR/Cas9 technology to enable the digital detection of a target DNA sequence within intact genomic material.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

In contrast to classical methods for the detection of nucleic acids, which require many reagents and expensive and bulky instrumentation, the "CRISPR-Chip" device developed by investigators at the University of California, Berkeley (USA) and the Keck Graduate Institute (Claremont, CA, USA) exploited the gene-targeting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a specific single-guide RNA and immobilized on a graphene-based field-effect transistor. This created a label-free nucleic-acid-testing device whose output signal could be measured with a simple handheld reader.

Mechanistically, the CRISPR complex located the target DNA site on the genome, bound to it, and triggered a change in the electrical conductance of the graphene, which, in turn, changed the electrical characteristics of the transistor. These changes were detected with a hand-held device.

The investigators used CRISPR–Chip to analyze DNA samples collected from HEK293T cell lines expressing blue fluorescent protein, and clinical samples of DNA with two distinct mutations at exons commonly deleted in individuals with Duchenne muscular dystrophy. In the presence of genomic DNA containing the target gene, CRISPR–Chip generated, within 15 minutes and without the need for amplification, a significant enhancement in output signal relative to samples lacking the target sequence.

"We have developed the first transistor that uses CRISPR to search your genome for potential mutations," said senior author Dr. Kiana Aran, assistant professor of medical diagnostics and therapeutics at the Keck Graduate Institute. "You just put your purified DNA sample on the chip, allow CRISPR to do the search and the graphene transistor reports the result of this search in minutes. Graphene's super-sensitivity enabled us to detect the DNA searching activities of CRISPR. CRISPR brought the selectivity, graphene transistors brought the sensitivity and, together, we were able to do this PCR-free or amplification-free detection. Combining modern nanoelectronics with modern biology opens a new door to get access to new biological information that was not accessible before."

The CRISP-Chip device was described in the March 25, 2019, online edition of the journal Nature Biomedical Engineering.

Related Links:
University of California, Berkeley
Keck Graduate Institute

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more